Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Scrip Team

Latest From Scrip Team

Coronavirus Update: WHO Suspends Hydroxychloroquine Trial, Novavax Launches Phase I/II Vaccine Study

Mounting evidence that President Trump's 'game changer' does more harm than good for COVID-19 patients. Novovax and Medicago among the latest vaccine developers to report progress.

Coronavirus COVID-19 Clinical Trials

Coronavirus Update: AZ Gets $1bn From US, Secures Capacity For One Billion Vaccine Doses

Inovio vaccine data published, US government invests to protect, generic remdesivir launched in Bangladesh.

Companies Coronavirus COVID-19

Coronavirus Update: Gilead Ready To Unveil Remdesivir Price

Gilead is preparing to unveil its long-term commercial plan for the antiviral therapy, including its expectations on prices and profits.

Coronavirus COVID-19 Companies

Coronavirus Update: Ex-GSK Exec To Lead Trump's Operation Warp Speed

US government will fund 'at risk' manufacturing of lead vaccine candidates, with Trump promising US will get priority. But skeptics say year-end timeline is unrealistic.

Coronavirus COVID-19 Politics

Coronavirus Update: EU Regulator Skeptical On Vaccine This Year, Takeda Prepares Hyperimmune Alliance

EMA leader doesn't share Oxford's optimism, Takeda-led alliance forges ahead with plasma-derived therapy plans, Indian pharma firm Cadila gets into testing kits.

Coronavirus COVID-19 Research & Development

Coronavirus Update: Moderna's Vaccine Frontrunner Gets Fast-Tracked, Wuhan To Test Millions

Moderna gets green light to proceed to Phase II trial of mRNA vaccine, with its eagerly-awaited Phase I results expected shortly.

Coronavirus COVID-19 Companies
See All
UsernamePublicRestriction

Register